Acquire Develop Out-License

To beat cancer
we need to think like cancer

Constantly Evolving

Seeking breakthrough therapies that open up areas of unmet need

Continually Multiplying

We have a scalable platform that can advance multiple clinical trials

Rapidly accelerating

By speeding up drug development we can get successful products into patients quicker

Selecting promising drugs at any stage of development

Advancing these treatments through the clinic rapidly

Ellipses was created to accelerate cancer treatment discoveries. We do this by ensuring more resource goes into potential drugs as soon as it is required, so that patients receive the benefit earlier

Oncology-focused precision medicine

We acquire high-quality drugs for clinical development

Any cancer

Our tumour-agnostic approach develops targeted treatments for any cancer type, giving patients the options they need

Any mechanism

We develop drugs with any validated mechanism of action or platform to address an unlimited number of cancer types

Any molecule

By being open to develop any molecule for cancer, we increase opportunities for success for patients and partners

Permanent source of capital
Reducing development delays

Reducing development delays

We have a permanent fixed source of funding that allows us to speed up pre-clinical and clinical development of partnered assets

Search, evaluate and acquire

We are custodians of the potential treatment from the acquisition stage, through clinical trials to out-license

  • Origin

    We uncover exceptional treatments, typically at the pre-clinical to Phase 1 stage, from academia, biotech & pharma partners

  • Evaluation

    We review exciting drugs with promising science, high quality data and the potential to positively impact patients and use our Scientific Affairs Group to support selection

  • Community

    We actively assess the market to ensure in-licensed treatments are developed to accompany existing standards of care

  • Out-License

    Successfully developed drugs are out-licensed at the appropriate point to maximise benefit to patients and partners

Our scientific affairs group

Develop

Advancing
multiple trials

Out-license

Speeding up drug
development

We are at the forefront of innovative clinical studies, using multiple different types of novel trials to optimise success

Right trial

Choosing the tumour

We understand the tumour types that will respond to the drug that we want to trial

Right patient

Choosing the patient

Patient selection results in smaller, more focused trials with a greater chance of success

Right trial
Right time
Right patient

Allowing us to develop more drugs and deliver more options to patients

  • Design

    We design novel, high-quality trials, utilising our Scientific Affairs Group, an omic's-driven approach and an appreciation of regulatory pathways

  • Right trial

    Manage

    Our in-house drug development team drives patient recruitment strategies, helping to achieve efficiencies, and protect against value erosion

  • Right time

    Facilitate

    We embed our specialist trial managers into the trial interface to have a direct representative between the CRO and trial centre

  • Right patient

    Scale

    Our operations are entirely scalable to grow alongside the acquisition of new assets and to ensure we can always run clinical trials simultaneously

  • Expertly designed clinical trials, with market potential

    Our Scientific Affairs Group supplies our trial team with continued insight throughout the clinical development process, determining how best to develop treatments

Our drug development roadmap

Acquire

Seeking breakthrough
therapies

Out-license

Speeding up drug
development

We are at the forefront of innovative clinical studies, using multiple different types of novel trials to optimise success

  • Design

    We design novel, high-quality trials, utilising our Scientific Affairs Group, an omic's-driven approach and an appreciation of regulatory pathways

  • Manage

    Our in-house drug development team drives patient recruitment strategies, helping to achieve efficiencies, and protect against value erosion

    Right trial

    We understand the tumour types that will respond to the drug that we want to trial

    Choosing the tumour

  • Facilitate

    We embed our specialist trial managers into the trial interface to have a direct representative between the CRO and trial centre

    Right time

    Allowing us to develop more drugs and deliver more options to patients
  • Scale

    Our operations are entirely scalable to grow alongside the acquisition of new assets and to ensure we can always run clinical trials simultaneously

    Right patient

    Patient selection results in smaller, more focused trials with a greater chance of success

    Choosing the patient

Expertly designed clinical trials, with market potential

Our Scientific Affairs Group supplies our trial team with continued insight throughout the clinical development process, determining how best to develop treatments

Our drug development roadmap

Acquire

Seeking breakthrough
therapies

Out-license

Speeding up drug
development

Value for partners

Value for patients

Accelerated trial completion and lower development costs can realise earlier benefit for both pharmaceutical partners and patients

Speed and scale

Our rapidly extensible portfolio transforms our potential to improve the lives of patients

We have a strong pipeline of clinical opportunities and we can scale globally

driving increased downstream value for treatments and patients

Our portfolio approach to investment enables us to optimise resources and accelerate drug development

We accelerate development

Trial
Trial
Trial
Value added

We save more lives

We capitalise for the company as a whole, not a single trial so that in-licensed assets are allocated funding as soon as they need it, rather than having to wait for the capital from specific fundraising rounds

We can achieve

  • Quicker trial completion
  • Lower cost of development
  • Increased value of treatments
  • Faster route to market
  • Earlier benefit to patients
Developed medicines

Acquire

Seeking breakthrough
therapies

Develop

Advancing
multiple trials

Value for partners

Value for patients

Accelerated trial completion and lower development costs can realise earlier benefit for both pharmaceutical partners and patients

Speed and scale

Our rapidly extensible portfolio transforms our potential to improve the lives of patients

We accelerate development

We have a strong pipeline of clinical opportunities and we can scale globally

Our model vs traditional model

Driving increased downstream value for treatments and patients

Our portfolio approach to investment enables us to optimise resources and accelerate drug development

Trial
Fundraise
Trial
Fundraise
Trial
Ellipses model
Fundraise
Trial
Value added
Traditional model

We capitalise for the company as a whole, not a single trial so that in‑licensed assets are allocated funding as soon as they need it, rather than having to wait for the capital from specific fundraising rounds

Watch video

We save more lives

We can achieve

  • Quicker trial completion
  • Lower cost of development
  • Increased value of treatments
  • Faster route to market
  • Earlier benefit to patients

Acquire

Seeking breakthrough
therapies

Develop

Advancing
multiple trials